Showing results (11-20 of 27) with videos related to
Sort By:
Pageof 3
Plos One|January 7, 2014
Human A53T α-synuclein causes reversible deficits in mitochondrial function and dynamics in primary mouse cortical neuronsLi Li, Sashi Nadanaciva, Zdenek Berger, et al.CNS Drugs|January 26, 2022
Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic ModelDrew MacCannell, Zdenek Berger, Janbernd Kirschner, et al.Neuromuscular Disorders : NMD|March 30, 2021
Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersenDrew MacCannell, Zdenek Berger, Lilly East, et al.Nature Genetics|May 18, 2004
Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington diseaseBrinda Ravikumar, Coralie Vacher, Zdenek Berger, et al.Human Molecular Genetics|December 22, 2005
Rapamycin alleviates toxicity of different aggregate-prone proteinsZdenek Berger, Brinda Ravikumar, Fiona M Menzies, et al.Annals of Clinical and Translational Neurology|May 14, 2022
Scientific rationale for a higher dose of nusinersenRichard S Finkel, Monique M Ryan, Samuel Ignacio Pascual Pascual, et al.CPT: Pharmacometrics & Systems Pharmacology|December 6, 2022
A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersenAlessio Paris, Pranami Bora, Silvia Parolo, et al.The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 6, 2007
Accumulation of pathological tau species and memory loss in a conditional model of tauopathyZdenek Berger, Hanno Roder, Amanda Hanna, et al.Journal of Clinical Medicine|August 12, 2023
Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor FunctionSally Dunaway Young, Jacqueline Montes, Allan M Glanzman, et al.Journal of Neuromuscular Diseases|July 2, 2023
DEVOTE Study Exploring Higher Dose of Nusinersen in Spinal Muscular Atrophy: Study Design and Part A ResultsRichard S Finkel, John W Day, Samuel Ignacio Pascual Pascual, et al.Pageof 3